Bladder Cancer, Kidney Cancers, Prostate Cancer
Conditions
Brief summary
This is a study : * Single-center * Prospective * Translational * Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project. The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. Translated with DeepL.com (free version)
Interventions
BIOLOGICALBlood sample
An additional 10 ml blood sample taken during a routine blood test
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: * Criteria common to all patients: * Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677); * affiliated with a social security health insurance scheme or beneficiary of such a scheme; * agreeing to participate in the 3DBlood study. * Specific criteria for patients with renal cell carcinoma (RCC): * Extended nephrectomy (EN) (larger tumor, closer to the sinus; therefore at greater risk of metastasis): with a cavo, cavectomy (neoplastic thrombus in the vena cava), or renal vein bud, or lymph node dissection, or with adrenalectomy (often for tumors, therefore possible metastases). Or \- Partial nephrectomy (PN): with tumors at stage T2 or T3a)
Exclusion criteria
* Patient refusal to participate in the study; * Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.); * Patient under legal protection, guardianship, or conservatorship; * Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. | Day 1 after surgery | For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor. |
Countries
France
Contacts
CONTACTHervé LANG, PUPH
Outcome results
None listed